Q4 2025 Management View Daniel O'Connell, CEO, highlighted 2025 as "a year of execution and expansion at Acumen." He reported demonstrable progress for the lead program, sabirnetug, in the Phase II ...
Lineage’s COR1 targets restoration of endothelial pump function via intracameral delivery and adhesion to Descemet membrane, ...
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN webinar, ...
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company ...
This breakthrough has accelerated peptide drug development across multiple therapeutic areas, including cardiovascular ...
Polyrizon Ltd., a biotechnology company focused on intranasal drug delivery systems, has reported promising preclinical results for its hydrogel-based Trap & Target (T&T) platform, developed in ...
Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to ...
The field of cancer immunology has seen significant advancements in recent years, particularly with the emergence of immunotherapy as a key pillar in the ...
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results